189 related articles for article (PubMed ID: 28546143)
21. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
22. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N; Sidana S; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Buadi FK; Fonder AL; Hayman SR; Hwa YL; Hobbs MA; Kapoor P; Gonsalves WI; Leung N; Go RS; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2018 Jan; 93(1):17-22. PubMed ID: 28960427
[TBL] [Abstract][Full Text] [Related]
23. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.
Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V
Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776
[TBL] [Abstract][Full Text] [Related]
24. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
25. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
26. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
[TBL] [Abstract][Full Text] [Related]
27. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
[No Abstract] [Full Text] [Related]
28. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
[TBL] [Abstract][Full Text] [Related]
29. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Zeldenrust SR; Tan T; Sinha S; Leung N; Kyle RA; Rajkumar SV; Gertz MA
Am J Hematol; 2011 Mar; 86(3):251-5. PubMed ID: 21328431
[TBL] [Abstract][Full Text] [Related]
31. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].
Li L; Jiang H; Fu WJ; Du J; He HY; Lu J; An R; He J; Zhang H; Zhao YY; Wu H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):321-326. PubMed ID: 31104445
[No Abstract] [Full Text] [Related]
34. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL; Warsame R; Gertz MA; Buadi FK; Lacy MQ; Kumar SK; Dingli D; Zeldenrust SR; Leung N; Hayman SR; Kapoor P; Gonsalves WI; Kourelis TV; Russell S; Go RS; Hobbs MA; Fonder AL; Rajkumar SV; Dispenzieri A
Blood; 2017 Sep; 130(13):1578-1584. PubMed ID: 28807981
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis.
Mollee P; Tate J; Pretorius CJ
Clin Chem Lab Med; 2013 Dec; 51(12):2303-10. PubMed ID: 23934643
[TBL] [Abstract][Full Text] [Related]
36. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
[TBL] [Abstract][Full Text] [Related]
37. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
38. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
40. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
